Bristol Myers Squibb disclosed the death of one patient after receiving its investigational autoimmune CAR-T in an early Phase 1 trial in multiple sclerosis. The patient developed motor symptoms that did not resolve with standard autoimmune treatments, then received an immunosuppressant and subsequently developed septic pneumonia before dying. The disclosure adds to a growing safety debate around autoimmune CAR-T, after Bristol paused related studies following “transient and reversible inflammatory events” seen during routine surveillance, and Novartis later reported three CAR-T autoimmune deaths tied to overactive immune responses. For the field, the key issue is whether CAR-T-associated inflammatory syndromes can be mitigated through earlier detection, modified conditioning, and escalation pathways while preserving efficacy. For investors and trial designers, the report also raises questions about how quickly programs should adapt protocols as rare but severe events emerge. Regulatory and clinical stakeholders are now likely to scrutinize future autoimmune CAR-T study surveillance, stop rules, and treatment algorithms more closely.